Loading...
NPI 1346648870 · Bethlehem, PA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Principle Labs LLC is a clinical medical laboratory provider located in Bethlehem, Pennsylvania. This profile covers 42 Medicare and 104 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Principle Labs LLC |
| Address | 2550 Brodhead Rd |
| City | Bethlehem |
| State | PA |
| ZIP | 18020 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 16, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $46.3M |
| Medicare | $4.5M |
PRINCIPLE LABS LLC is a clinical medical laboratory with an NPI enumerated ~12 years ago (2014-12-16), indicating established operations and at least a decade of Medicare/Medicaid participation. Tenure of this length supports the build-out of high-volume analytic workflows and sustained payer relationships for lab testing services.
Medicaid dominates this provider’s lifetime revenue by scale: total Medicaid revenue is $46.3M versus total Medicare revenue of $4.5M, making the organization effectively Medicaid-focused in raw revenue terms. This payer mix implies operational emphasis on Medicaid contracts, specimen volume, and workflows that serve Medicaid-covered populations or programs.
Medicare revenue is concentrated: the top 3 Medicare codes by revenue account for 63.7% of the provider’s total Medicare revenue, with 87798 alone contributing $1.9M (42.3% of Medicare revenue). That concentration, centered on nucleic acid/amplified probe testing codes, indicates the provider’s Medicare business is heavily weighted to molecular infectious-agent testing rather than broad-spectrum clinical chemistry.
Medicaid revenue is even more concentrated: the top 3 Medicaid codes by revenue account for 89.4% of the provider’s total Medicaid revenue, driven primarily by high-volume drug testing codes G0481 ($18.5M, 40.2% of Medicaid), G0480 ($12M, 26.0% of Medicaid), and presumptive drug screen 80307 ($10.7M, 23.3% of Medicaid). This mix indicates the lab operates at scale in definitive and presumptive drug testing services for Medicaid, likely supporting large collection networks, SUD programs, or managed care behavioral health workflows.
The provider is a notable outlier on several drug-testing codes in Medicaid: G0481 ranks #1 of 23 in-state and is labeled an "extreme outlier, far above typical state volume," while G0480 and 80307 each rank in the top 5 in-state (97th–98th percentile). These rankings reflect dominant in-state market share for definitive and presumptive drug testing and suggest high throughput capacity and strong referral or contract relationships for toxicology services.
On Medicare, PRINCIPLE LABS shows above-typical national volume for multiple amplified-probe infectious-agent codes: 87798 ranks in the 98th percentile nationally, and codes such as 87640, 87500, and 87641 rank in the mid-to-high 90th percentiles. These competitive standings indicate the lab is a significant national contributor for certain molecular infectious disease tests, even though its absolute Medicare revenue is modest relative to Medicaid.
Several individual Medicare codes show unusually high national rank for a lab of this profile—87563 ranks #6 of 256 (98th percentile) and 87491 ranks #18 of 530 (97th percentile)—which points to focused clinical test lines (e.g., Mycoplasma genitalium, Chlamydia) where the provider performs substantially more testing than most peers. These strengths mirror the amplified-probe testing specialization seen across both payers.
The revenue mix and top codes imply an operational model combining high-volume toxicology (Medicaid-focused) with specialized molecular infectious disease testing (Medicare presence and additional Medicaid services). Payer-level concentration risks: because 89.4% of Medicaid revenue comes from the top three codes and 63.7% of Medicare revenue from the top three codes, the business is sensitive to reimbursement and utilization shifts in a small set of service lines.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
42 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 55,740 | $30 | $1.9M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,650 | $200 | $516.2K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 12,940 | $30 | $440K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,710 | $60 | $165.3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,390 | $110 | $155.7K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 4,130 | $30 | $140.3K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 4,100 | $30 | $139.5K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 4,090 | $30 | $139.1K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 4,030 | $30 | $137K |
| 87563 | he lab analyst performs a test on a patient specimen such as blood, for Mycoplasma genitalium antigen detection using amplified nucleic acid probe technique. | 3,960 | $30 | $134.5K |
Showing 1–10 of 42
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 42 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
42 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 5 | 40 | 1,250 | $30 | $1.1M |
| 87481 | 5 | 20 | 940 | $30 | $574.2K |
| 87653 | 5 | 20 | 360 | $30 | $175.8K |
| 81226 | 3 | 10 | 220 | $440 | $117.7K |
| 87563 | 2 | 10 | 1,340 | $30 | $116K |
| 87625 | 2 | 10 | 70 | $40 | $107.4K |
| U0004 | 6 | 10 | 190 | $70 | $105.8K |
| 87529 | 2 | 10 | 80 | $30 | $96.6K |
| G0480 | 7 | 40 | 270 | $110 | $94.5K |
| 87500 | 5 | 30 | 110 | $30 | $94.4K |
Showing 1–10 of 42
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
104 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 150,170 | $120 | $18.5M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 145,740 | $80 | $12M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 237,740 | $50 | $10.7M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 15,240 | $100 | $1.5M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 7,290 | $110 | $816.7K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 8,510 | $80 | $646.8K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 2,850 | $200 | $557.8K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,240 | $150 | $486.6K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 6,660 | $30 | $166.5K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 6,530 | $10 | $78.4K |
Showing 1–10 of 104
How this provider's Medicaid billing volume and revenue compare to other Pennsylvania providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Pennsylvania median
104 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 20 | 710 | $80 | $1.7M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 130 | 310 | $60 | $769.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 5 | 210 | 730 | $40 | $689.7K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 9 | 20 | 3,040 | $60 | $483.4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 13 | 70 | 620 | $60 | $464.8K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 20 | 540 | $50 | $367.6K |
| 81226 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily D, polypeptide 6, also known as CYP2D6. | 5 | 10 | 110 | $40 | $149.3K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 13 | 30 | 220 | $30 | $139.6K |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 5 | 10 | 110 | $30 | $135.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 5 | 70 | 270 | $50 | $108.2K |
Showing 1–10 of 104
Other providers in the same ZIP code as Principle Labs LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Royal Homestar LLC | PA | Durable Medical Equipment & Medical Supplies | $0 | $22.6M |
| Aba Support Services LLC | PA | Community/Behavioral Health Agency | $0 | $10.4M |
| New Directions Treatment Services | PA | Methadone Clinic | $0 | $5.6M |
| Bethlehem Township Volunteer Fire Company | PA | Land Ambulance | $982.2K | $1.7M |
| Lehigh Valley Toxicology LLC | PA | Clinical Medical Laboratory | $673.2K | $1.6M |
| The Center For Specialized Surgery, LP | PA | Ambulatory Surgical Clinic/Center | $2M | $0 |
| New Directions Treatment Services | PA | Community/Behavioral Health Agency | $353.3K | $972.6K |
| Valley Surgical Center Inc | PA | Ambulatory Surgical Clinic/Center | $247.2K | $790.8K |
| Vladimir Alhov | PA | Physical Medicine & Rehabilitation Physician | $213.8K | $13.3K |
| Amit Malhotra | PA | Diagnostic Radiology Physician | $155.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.